GlassScriptPhysician profile
Kenneth Wogensen
NPI 1932109295
$26,540.73
in general payments reported to CMS, 2019-2025
79 companies · $4,269 in 2025
The $4,269 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,795 · 2020: $2,820 · 2021: $3,838 · 2022: $3,917 · 2023: $3,761 · 2024: $4,140 · 2025: $4,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,885.23 |
| Education | $285.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,215.15 | 2019-2025 | Rystiggo, Zilbrysq, Fintepla |
| Biogen, INC. | $2,159.91 | 2020-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $1,805.30 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,669.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,645.92 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Alexion Pharmaceuticals, INC. | $1,402.43 | 2019-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $1,385.57 | 2019-2025 | Nuplazid, Daybue |
| Eisai INC. | $1,125.40 | 2019-2025 | |
| Lilly USA, LLC | $927.96 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $894.27 | 2019-2025 | |
| Amgen INC. | $844.97 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $718.70 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $585.75 | 2019-2025 | Crexont, Rytary |
| Lundbeck LLC | $562.77 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $486.25 | 2019-2025 | Mavenclad |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wogensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.